{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:37:41Z","timestamp":1762900661743,"version":"3.41.2"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Gout is a common inflammatory arthritis and lipid metabolism plays a crucial role in urate and gout. Potential associations between urate and gout and lipid-lowering drugs have been revealed in observational studies. However, the effects of lipid-lowering drugs on urate and gout remain controversial. The aim of this study was to investigate the genetic association between lipid-lowering drugs and urate and gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, two genetic proxies were employed to approximate lipid-lowering drug exposure: expression quantitative trait loci (eQTL) associated with drug-target genes and genetic variations proximal to or within genes targeted by these drugs, which are linked to low-density lipoprotein cholesterol (LDL-C) levels. The study\u2019s exposures encompassed genetic variants within drug target genes (HMGCR, PCSK9, NPC1L1), each representing distinct lipid-lowering mechanisms. Causal effects were estimated using the inverse variance weighting (IVW) method, while the Summary Data-based Mendelian Randomization (SMR) method, leveraging pooled data, was applied to compute effect estimates. These estimates were further refined through various approaches including MR-Egger, the weighted median method, simple and weighted models, and leave-one-out analyses to conduct sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>The analytical outcomes utilizing the IVW method indicated that inhibitors of HMGCR were correlated with an elevated risk of developing gout (IVW: OR [95%CI] = 1.25 [1.03, 1.46], p=0.0436), while PCSK9 inhibitors were linked to heightened levels of urate (IVW: OR [95%CI] = 1.06 [1.01,1.10], p=0.0167). Conversely, no significant correlation between NPC1L1 inhibitors and the levels of urate or the risk of gout was established. Furthermore, the SMR analysis failed to identify significant associations between the expression levels of the HMGCR, PCSK9, and NPC1L1 genes and the risk of gout or elevated urate levels (SMR method: all P values &amp;gt;0.05). Sensitivity analyses further confirmed the robustness of these results, with no significant heterogeneity or pleiotropy found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study furnishes novel causal evidence supporting the potential genetic correlation between the use of lipid-lowering drugs and the incidence of gout as well as urate levels. The findings indicate that inhibitors targeting HMGCR may elevate the risk associated with the development of gout, while inhibitors targeting PCSK9 are likely to increase urate concentrations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1398023","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:21:58Z","timestamp":1737696118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Associations between lipid-lowering drugs and urate and gout outcomes: a Mendelian randomization study"],"prefix":"10.3389","volume":"15","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyuan","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrrheum.2012.143","article-title":"Uric acid as a danger signal in gout and its comorbidities","volume":"9","author":"Rock","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12916-017-0878-5","article-title":"The genetics of gout: towards personalised medicine","volume":"15","author":"Dalbeth","year":"2017","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.v72.11","article-title":"Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: A systematic analysis of the global burden of disease study 2017","volume":"72","author":"Safiri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12944-020-01211-z","article-title":"Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008-2012)","volume":"19","author":"Liu","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228684","article-title":"Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017","volume":"15","author":"Son","year":"2020","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12944-020-1197-y","article-title":"The comparison of dyslipidemia and serum uric acid in patients with gout and asymptomatic hyperuricemia: a cross-sectional study","volume":"19","author":"Liang","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12040605","article-title":"Association between gout and dyslipidemia: A nested case-control study using a national health screening cohort","volume":"12","author":"Choi","year":"2022","journal-title":"J Pers Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01075-w","article-title":"Bempedoic acid: A new non-statin drug for the treatment of dyslipidemia","volume":"41","author":"Wichaiyo","year":"2021","journal-title":"Clin Drug Investig"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25642","article-title":"Lipid lowering and Alzheimer disease risk: A mendelian randomization study","volume":"87","author":"Williams","year":"2020","journal-title":"Ann Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian randomization study of PCSK9 and HMG-coA reductase inhibition and cognitive function","volume":"80","author":"Rosoff","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-012110-142233","article-title":"Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport","volume":"73","author":"Jia","year":"2011","journal-title":"Annu Rev Physiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003410","article-title":"Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study","volume":"17","author":"Rosoff","year":"2020","journal-title":"PLoS Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2022.01.004","article-title":"Safety of statins and nonstatins for treatment of dyslipidemia","volume":"51","author":"Newman","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2741131","DOI":"10.1155\/2021\/2741131","article-title":"Association between lipid profiles and serum urate: A cross-sectional study in Southwestern China","volume":"2021","author":"Qi","year":"2021","journal-title":"Int J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"R170","DOI":"10.1093\/hmg\/ddz204","article-title":"Within family Mendelian randomization studies","volume":"28","author":"Davies","year":"2019","journal-title":"Hum Mol Genet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"Bmj"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"Jama"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression","volume":"53","author":"V\u00f5sa","year":"2021","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","volume":"369","year":"2020","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"Jama"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0504-x","article-title":"Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels","volume":"51","author":"Tin","year":"2019","journal-title":"Nat Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3538","article-title":"Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets","volume":"48","author":"Zhu","year":"2016","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0255-x","article-title":"Interpreting findings from Mendelian randomization using the MR-Egger method","volume":"32","author":"Burgess","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6522","article-title":"Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome","volume":"34","author":"Greco","year":"2015","journal-title":"Stat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx034","article-title":"MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data","volume":"46","author":"Yavorska","year":"2017","journal-title":"Int J Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew293","article-title":"Drug-induced hyperuricaemia and gout","volume":"56","author":"Ben Salem","year":"2017","journal-title":"Rheumatology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2174\/1381612811319130011","article-title":"Chronic hyperuricemia, uric acid deposit and cardiovascular risk","volume":"19","author":"Grassi","year":"2013","journal-title":"Curr Pharm design"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/127596","article-title":"Relationship between hyperuricemia and lipid profiles in US adults","volume":"2015","author":"Peng","year":"2015","journal-title":"BioMed Res Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/acr.2019.71.issue-7","article-title":"Patients with early-onset gout and development of earlier severe joint involvement and metabolic comorbid conditions: results from a cross-sectional epidemiologic survey","volume":"71","author":"Pascart","year":"2019","journal-title":"Arthritis Care Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"16767","DOI":"10.1038\/s41598-018-35175-z","article-title":"Effect of fenofibrate on uric acid level in patients with gout","volume":"8","author":"Jung","year":"2018","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab231","article-title":"Effects of fenofibrate therapy on renal function in primary gout patients","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: A systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies","volume":"43","author":"Cicero","year":"2020","journal-title":"Drug Saf"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa822","article-title":"Effects of bariatric surgery on serum uric acid in people with obesity with or without hyperuricaemia and gout: a retrospective analysis","volume":"60","author":"Lu","year":"2021","journal-title":"Rheumatology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key229","article-title":"Genetic association between adiposity and gout: a Mendelian randomization study","volume":"57","author":"Larsson","year":"2018","journal-title":"Rheumatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130013","article-title":"Impact of diabetes against the future risk of developing gout","volume":"69","author":"Rodr\u00edguez","year":"2010","journal-title":"Ann rheumatic Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"22558","DOI":"10.1038\/s41598-023-49874-9","article-title":"Fenofibrate reduces glucose-induced barrier dysfunction in feline enteroids","volume":"13","author":"Crawford","year":"2023","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa258","article-title":"Association between statin use and inflammatory bowel diseases","volume":"15","author":"Dai","year":"2021","journal-title":"J Crohn's Colitis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/imr.12833","article-title":"Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia","volume":"294","author":"Cab\u0103u","year":"2020","journal-title":"Immunol Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart Journal-Cardiovascular Pharmacotherapy"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1398023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:22:02Z","timestamp":1737696122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1398023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":53,"alternative-id":["10.3389\/fendo.2024.1398023"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1398023","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1398023"}}